Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 4 (2007), Issue 2 (February)

1. 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma.
   Cancer Sci, 98(3): 424-30. [Abstract] [Full-text]
2. Melanoma immunology: past, present and future.
   Curr Opin Oncol, 19(2): 121-7. [Abstract] [Full-text]
3. Current topics in melanoma.
   Curr Opin Oncol, 19(2): 116-20. [Abstract] [Full-text]
4. Early melanoma diagnosis: a success story that leaves room for improvement.
   Curr Opin Oncol, 19(2): 109-15. [Abstract] [Full-text]
5. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.
   Cancer Immunol Immunother, 56(4): 515-26. [Abstract] [Full-text]
6. Photoreceptor proteins as cancer-retina antigens.
   Int J Cancer, 120(6): 1268-76. [Abstract] [Full-text]
7. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target.
   Int J Cancer, 120(6): 1304-10. [Abstract] [Full-text]
8. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells.
   Int J Cancer, 120(6): 1364-71. [Abstract] [Full-text]
9. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
   Cancer Res, 67(3): 1221-7. [Abstract] [Full-text]
10. Role of microphthalmia transcription factor (Mitf) in melanoma differentiation.
    Biochem Biophys Res Commun, 354(3): 830-5. [Abstract] [Full-text]
11. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.
    Br J Cancer, 96(3): 445-9. [Abstract] [Full-text]
12. Loss of oncostatin M receptor beta in metastatic melanoma cells.
    Oncogene, 26(6): 881-92. [Abstract] [Full-text]
13. Activity of matrix metalloproteinase-2 (MMP-2) in canine oronasal tumors.
    Res Vet Sci, 82(2): 271-9. [Abstract] [Full-text]
14. Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: a Phase I/II dose-escalation study.
    Int J Radiat Oncol Biol Phys, 67(3): 857-62. [Abstract] [Full-text]
15. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis.
    Biochem Biophys Res Commun, 354(4): 985-91. [Abstract] [Full-text]
16. Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.
    J Invest Dermatol, 127(3): 622-9. [Abstract] [Full-text]
17. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Cancer Gene Ther, 14(3): 262-7. [Abstract] [Full-text]
18. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
    Oncogene, 26(7): 1056-66. [Abstract] [Full-text]
19. Tumoral melanosis involving the sentinel lymph nodes: a case report.
    J Cutan Pathol, 34(3): 284-6. [Abstract] [Full-text]
20. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings.
    J Cutan Pathol, 34(3): 247-56. [Abstract] [Full-text]
21. E-cadherin and beta-catenin expression patterns in malignant melanoma assessed by image analysis.
    J Cutan Pathol, 34(3): 239-46. [Abstract] [Full-text]
22. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
    J Cutan Pathol, 34(3): 220-5. [Abstract] [Full-text]
23. Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines.
    Biochem Pharmacol, 73(6): 773-81. [Abstract] [Full-text]
24. Prognostic scoring in patients with melanoma after adjuvant isolated limb perfusion.
    J Surg Res, 138(1): 22-4. [Abstract] [Full-text]
25. mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB.
    Cancer Res, 67(4): 1812-22. [Abstract] [Full-text]
26. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.
    Cancer Res, 67(4): 1725-34. [Abstract] [Full-text]
27. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
    Cancer Res, 67(4): 1502-12. [Abstract] [Full-text]
28. Reproductive risk factors for cutaneous melanoma in women: a case-control study.
    Am J Epidemiol, 165(5): 505-13. [Abstract] [Full-text]
29. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
    Gynecol Oncol, 104(3): 564-71. [Abstract] [Full-text]
30. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy.
    J Natl Cancer Inst, 99(4): 309-21. [Abstract] [Full-text]
31. Diagnosis and treatment of interval sentinel lymph nodes in patients with cutaneous melanoma.
    Plast Reconstr Surg, 119(3): 907-13. [Abstract] [Full-text]
32. Melanoma biology and new targeted therapy.
    Nature, 445(7130): 851-7. [Abstract] [Full-text]
33. Xanthogranuloma of the iris simulating melanoma in an adult.
    Am J Ophthalmol, 143(3): 529-31. [Abstract] [Full-text]
34. Imiquimod as an antiaging agent.
    J Am Acad Dermatol, 56(3): 422-5. [Abstract] [Full-text]
35. Factors influencing participation in cutaneous screening among individuals with a family history of melanoma.
    J Am Acad Dermatol, 56(3): 398-406. [Abstract] [Full-text]
36. Dispelling the myth of the "benign hair sign" for melanoma.
    J Am Acad Dermatol, 56(3): 413-6. [Abstract] [Full-text]
37. Examination of mediating variables in a partner assistance intervention designed to increase performance of skin self-examination.
    J Am Acad Dermatol, 56(3): 391-7. [Abstract] [Full-text]
38. Dermoscopy features of melanoma incognito: indications for biopsy.
    J Am Acad Dermatol, 56(3): 508-13. [Abstract] [Full-text]
39. Characterization and antitumor activity of pollen polysaccharide.
    Int Immunopharmacol, 7(4): 427-34. [Abstract] [Full-text]
40. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.
    Invest Ophthalmol Vis Sci, 48(3): 1219-27. [Abstract] [Full-text]
41. Manganese-enhanced MRI of human choroidal melanoma xenografts.
    Invest Ophthalmol Vis Sci, 48(3): 963-7. [Abstract] [Full-text]
42. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
    Nucl Med Commun, 28(4): 273-80. [Abstract] [Full-text]
43. Gamma knife radiosurgery in the management of malignant melanoma brain metastases.
    Neurosurgery, 60(3): 471-81; discussion 481-2. [Abstract] [Full-text]
44. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    J Clin Oncol, 25(7): 869-75. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.